Notice of Proposed Sale · 144
Travere Therapeutics, Inc.
TVTXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- TRAVERE THERAPEUTICS, INC.
- Issuer CIK
- 0001438533
- SEC file number
- 001-36257
- Phone
- 8889697879
- Person for whose account securities are to be sold
- JULA INRIG
- Relationships to issuer
- Officer
- Street
- 3611 Valley Centre Drive, Suite 300
- City
- San Diego
- State / country code
- CA
- Postal code
- 92130
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 44,674 | 2,939,102.46 | 94,261,082 | 09/15/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 09/15/2026 | Exercise of Stock Options | Issuer | 32,395 | N | 09/15/2026 | Cash |
| Common | 01/01/2023 | Restricted Stock Units | Issuer | 7,662 | N | 01/01/2023 | N/A |
| Common | 02/10/2025 | Performance Stock Units | Issuer | 4,617 | N | 02/10/2025 | N/A |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
The securities to be sold were acquired upon the vesting of restricted stock units during the period of 01/01/2023 through 01/31/2025
Notice signature
- Notice date
- 09/15/2026
- Signed
- /s/ Jula Inrig
- Plan adoption dates
- 06/16/2026
Company context
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent - that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope - today and tomorrow. For more information, visit travere.com.
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by BANK OF AMERICA CORP /DE/ regarding Travere Therapeutics, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by FMR LLC regarding Travere Therapeutics, Inc.Nov 5, 2026
- 10-Q filingNov 2, 2026
- Results of Operations and Financial ConditionNov 2, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 21, 2026